<DOC>
	<DOCNO>NCT01845844</DOCNO>
	<brief_summary>This open-label , Phase I/II study Intravitreally administer 0.3mg ranibizumab subject persistent Diabetic Macular Edema ( DME ) recent frequent bevacizumab ( least 2 bevacizumab intravitreal injection within 2 month prior enrollment least 6 bevacizumab injection within 9 month enrollment ) .</brief_summary>
	<brief_title>Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab</brief_title>
	<detailed_description>30 eye randomize 1:2 ratio ( Group A= 10 patient ; Group B= 20 patient ) Group A : ( `` monthly group '' ) - Consented patient enrol eye receive 12 monthly require injection 0.3mg ranibizumab 1 year OR Group B : ( `` As need ( PRN ) Group '' ) - Consented patient enrol eye receive 6 monthly require injection 0.3mg ranibizumab 6 month , follow need ( PRN ) dosing ( require ranibizumab DME persistent Optical Coherence Tomography ( OCT ) Early Treatment Diabetic Retina Study ( ETDRS ) Best Corrected Visual Acuity ( BCVA ) &lt; 20/20 ) 6 month .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . &gt; =18 year Type I/II diabetes mellitus Centralinvolved DME study eye ( OCT CSF &gt; =275um Heidelberg Spectralis spectral domain OCT evidence intraretinal subretinal fluid cyst ) Definite retinal thickening due diabetic macular edema involve center macula . Media clarity , pupillary dilation individual cooperation adequate fungus photography fluorescein angiography . Visual Acuity score study eye &lt; =80 &gt; =20 ( approximate Snellen equivalent 20/25 20/400 ) . History least 6 intravitreal bevacizumab injection within past 9 month 2 intravitreal bevacizumab injection within past 2 month . No history antiVEGF treatment DME past 3 week . No DME treatment DME , bevacizumab , study eye time past 3 month . No history major ocular surgery study eye within prior 3 month anticipate within next six month follow randomization . Pregnancy lactation Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another medical investigation trial within 30 day randomization Known allergy ranibizumab Acute cardiovascular event require hospitalization within past 3 month Systemic antiVEGF proVEGF treatment within 3 month prior randomization anticipate use study Macular edema consider due cause DME An ocular condition present , opinion investigator , visual acuity loss would improve resolution macular edema History intravitreal antivascular endothelial growth factor ( antiVEGF ) agent bevacizumab within 9 month prior randomization History panretinal photocoagulation within 3 month prior randomization anticipate need panretinal photocoagulation 6 month follow randomization Yag capsulotomy perform within 1 month prior randomization External ocular infection include conjunctivitis , significant blepharitis , etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>